The Single Use Bioprocessing Market is being driven by the rapid expansion of biologics manufacturing and the growing need for flexible production infrastructure. Pharmaceutical and biotechnology companies are increasingly adopting disposable technologies because they can simplify manufacturing operations and reduce the need for extensive cleaning and sterilization processes.

The expanding pipeline of monoclonal antibodies, vaccines, cell therapies, and gene therapies is generating strong demand for bioprocessing equipment and consumables. Contract development and manufacturing organizations are another important growth driver because their multi-client operations benefit from faster equipment changeovers and reduced cross-contamination concerns.

According to the market report, biopharmaceutical companies accounted for approximately 69.5% of market revenue in 2025, while CDMOs represent the fastest-growing end-user segment, with a projected CAGR of 16.0% through 2035.

Technological developments are further strengthening market growth. Advanced sensors, automated process monitoring, and AI-enabled process analytical technology are improving manufacturing capabilities.

The increasing adoption of modular facilities and the development of new biologics manufacturing capacity in emerging markets are also contributing to demand. These factors collectively create favorable conditions for sustained expansion of the single-use bioprocessing industry.